BioEngine Announces Completion of Over 300 Million RMB Series C financing round to Promote “Intelligent Manufacturing” of the serum-free medium in China

Recently, China's leading company in animal cell culture technology and domestic serum-free culture media, Shanghai BioEngine Sci-Tech Co., LTd., announced the completion of over 300 million RMB Series C financing round. The funds will be used to accelerate the local Innovative research and development of serum-free medium, industrial service capabilities, and information construction, etc., to further build BioEngine into an industry-leading cell culture partner.

The financing was led by Newerli Capital, followed by Ningbo LEO, HM Capital, Kington Capital, C&D Emerging Industry Equity Investment and Riverhead Capital, and the old shareholder Addor Capital, Tsing Song Capital, and Legend Capital continued to increase the capital.

The serum-free medium, the core product of BioEngine, is a key raw material for the upstream process of biopharmaceuticals. Relying on the knowledge accumulation and technology precipitation of the founding team for more than 30 years, BioEngine has served more than 200 biopharmaceutical companies at home and abroad, comprehensive coverage of vaccines, antibodies and CGT fields. This financing is bound to bring a broader development space for the innovative R&D and market expansion of BioEngine “Intelligent Manufacturing in China” serum-free medium.